Biocytogen
Dr. Guo graduated from University of Goettingen & Max-Planck-Institute of Biophysical Chemistry, Germany and received a doctoral degree in Biochemistry in November, 2003, where he worked on the functional study of molecular chaperones via biochemistry, structural biology, and gene knockout mouse models. In 2005-2013, Dr. Guo has focused on cardiovascular and blood system development in Boston Children’s Hospital/Harvard Medical School. His research has been published in JCI, Development, and other highly reputed journals. Dr. Guo is experienced in animal model generation and phenotype analysis. In October, 2013, Dr. Guo served as the Senior R&D Director and Key Account Manager of Beijing Biocytogen Co., Ltd, to help the company establish CRISPR based gene editing platform and marketing promotion, and also got involved in humanized immune checkpoint animal model generation. Since June 2015, Dr. Guo served as the Vice President of Marketing and Global Head of Business Development.
This person is not in any offices
Biocytogen
2 followers
Biocytogen is a preclinical stage biotech that provides a one-stop solution for antibody discovery from target to IND application. With cutting-edge technologies, state-of-art animal facility, and world-class platforms for antibody drug discovery, Biocytogen offers animal model generation, antibody fully human-mouse (RenMab mouse), therapeutic antibody discovery and development, in vivo/in vitro preclinical studies, CMC/CDMO, and regulatory affairs support.